| Enzon presented data from its pipeline programs at the 2009 European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research annual meeting in Boston, Massachusetts. Jeffrey H. Buchalter, Enzon CEO, said, “Our PEG-SN38 continues to be well tolerated and demonstrates antitumor activity in previously treated patients with solid tumors. Additionally, our novel locked nucleic acid-based antagonists including Survivin, continue to show promise for inhibition of tumor growth in a variety of cancers.” :theflyonthewall.com |
Subscribe for More Information